{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:48:57Z","timestamp":1787759337169,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s11255-017-1507-0","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T11:27:09Z","timestamp":1484911629000},"page":"499-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750\u00a0mg\/day) or conventional intravenous\/oral levofloxacin (500\u00a0mg\/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial"],"prefix":"10.1007","volume":"49","author":[{"given":"Hong","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Hui","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ying","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Wen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Min","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ying","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"1507_CR1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1067\/mda.2003.7","volume":"49","author":"B Foxman","year":"2003","unstructured":"Foxman B (2003) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 49:53\u201370","journal-title":"Dis Mon"},{"key":"1507_CR2","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1128\/AAC.01257-13","volume":"57","author":"KP Singh","year":"2013","unstructured":"Singh KP, Li G, Mitrani-gold FS et al (2013) Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection. Antimicrob Agents Chemother 57:5284\u20135290","journal-title":"Antimicrob Agents Chemother"},{"key":"1507_CR3","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2174\/1389201014666131226144824","volume":"14","author":"DG Moriel","year":"2013","unstructured":"Moriel DG, Schembri MA (2013) Vaccination approaches for the prevention of urinary tract infection. Curr Pharm Biotechnol 14:967\u2013974","journal-title":"Curr Pharm Biotechnol"},{"key":"1507_CR4","first-page":"365","volume":"14","author":"FP Hu","year":"2014","unstructured":"Hu FP, Zhu DM, Wang Fu et al (2014) CHINET 2013 surveillance of bacterial resistance in China. Chin J Infect Chemother 14:365\u2013374","journal-title":"Chin J Infect Chemother"},{"key":"1507_CR5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2147\/TCRM.S3426","volume":"4","author":"JC Mcgregor","year":"2008","unstructured":"Mcgregor JC, Allen GP, Bearden DT (2008) Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis. Ther Clin Risk Manag 4:843\u2013853","journal-title":"Ther Clin Risk Manag"},{"key":"1507_CR6","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1185\/030079907X233340","volume":"22","author":"HA Klausner","year":"2007","unstructured":"Klausner HA, Brown P, Peterson J et al (2007) A trial of levofloxacin 750\u00a0mg once daily for 5\u00a0days versus ciprofloxacin 400\u00a0mg and\/or 500\u00a0mg twice daily for 10\u00a0days in the treatment of acute pyelonephritis. Curr Med Res Opin 22:2637\u20132645","journal-title":"Curr Med Res Opin"},{"key":"1507_CR7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2165\/00003495-200868040-00011","volume":"68","author":"VR Anderson","year":"2008","unstructured":"Anderson VR, Perry CM (2008) Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs 68:535\u2013565","journal-title":"Drugs"},{"key":"1507_CR8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0090-4295(98)00160-5","volume":"52","author":"GA Richard","year":"1998","unstructured":"Richard GA, Klimberg IN, Fowler CL et al (1998) Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. Urology 52:51\u201355","journal-title":"Urology"},{"key":"1507_CR9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1128\/AAC.31.7.1054","volume":"31","author":"J Blaser","year":"1987","unstructured":"Blaser J, Stone BB, Groner MC et al (1987) Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 31:1054\u20131060","journal-title":"Antimicrob Agents Chemother"},{"key":"1507_CR10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/AAC.37.3.483","volume":"37","author":"GL Drusano","year":"1993","unstructured":"Drusano GL, Johnson DE, Rosen M et al (1993) Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 37:483\u2013490","journal-title":"Antimicrob Agents Chemother"},{"key":"1507_CR11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1128\/AAC.37.5.1073","volume":"37","author":"A Forrest","year":"1993","unstructured":"Forrest A, Nix DE, Ballow CH et al (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37:1073\u20131081","journal-title":"Antimicrob Agents Chemother"},{"key":"1507_CR12","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1378\/chest.119.4.1114","volume":"119","author":"MH Gotfried","year":"2001","unstructured":"Gotfried MH, Danziger LH, Rodvold KA (2001) Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119:1114\u20131122","journal-title":"Chest"},{"key":"1507_CR13","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0732-8893(02)00417-0","volume":"44","author":"PD Lister","year":"2002","unstructured":"Lister PD (2002) Pharmacodynamics of 750\u00a0mg and 500\u00a0mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 44:43\u201349","journal-title":"Diagn Microbiol Infect Dis"},{"key":"1507_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2007.09.002","volume":"71","author":"J Peterson","year":"2008","unstructured":"Peterson J, Kaul S, Khashab M et al (2008) A double-blind, randomized comparison of levofloxacin 750\u00a0mg once-daily for 5\u00a0days with ciprofloxacin 400\/500\u00a0mg twice-daily for 10\u00a0days for the treatment of complicated urinary tract infections and acute pyelonephritis. Urology 71:17\u201322","journal-title":"Urology"},{"key":"1507_CR15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10156-009-0713-9","volume":"15","author":"YY Zhang","year":"2009","unstructured":"Zhang YY, Huang HH, Ren ZY et al (2009) Clinical evaluation of oral levofloxacin 500\u00a0mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China. J Infect Chemother 15:301\u2013311","journal-title":"J Infect Chemother"},{"key":"1507_CR16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2174\/1389201014666131226144824","volume":"14","author":"DG Moriel","year":"2013","unstructured":"Moriel DG, Schembri MA (2013) Vaccination approaches for the prevention of urinary tract infection. Curr Pharm Biotechnol 14:967\u2013974","journal-title":"Curr Pharm Biotechnol"},{"key":"1507_CR17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ijantimicag.2008.04.025","volume":"32","author":"GE Stein","year":"2008","unstructured":"Stein GE, Schooley SL, Nicolau DP (2008) Urinary bacterial activity of single doses (250,500,750 and 1000\u00a0mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli. Inter J Antimicrobial Agents 32:320\u2013325","journal-title":"Inter J Antimicrobial Agents"},{"key":"1507_CR18","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","volume":"385","author":"FM Wagenlehner","year":"2015","unstructured":"Wagenlehner FM, Umeh O, Steenbergen J et al (2015) Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385:1949\u20131956","journal-title":"Lancet"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1507-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-017-1507-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1507-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T20:18:52Z","timestamp":1568751532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-017-1507-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["1507"],"URL":"https:\/\/doi.org\/10.1007\/s11255-017-1507-0","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,20]]}}}